<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432937</url>
  </required_header>
  <id_info>
    <org_study_id>TSHCR1201</org_study_id>
    <nct_id>NCT02432937</nct_id>
  </id_info>
  <brief_title>Corever in the Treatment of Hypertension</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase III Study of Corever for the Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TSH Biopharm Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TSH Biopharm Corporation Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study primarily aims to compare the effects of two doses of Corever with placebo in&#xD;
      patients with hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to compare the effects of two doses of Corever with placebo in patients with&#xD;
      essential hypertension. Eligible subjects who belong to one of the following subtypes are&#xD;
      planned to be enrolled: (1) patients with essential hypertension without drug control, or (2)&#xD;
      uncontrolled hypertension despite treatment with up to 2 antihypertensive agents. Of note,&#xD;
      the second category will receive randomized study treatments in addition to continuing their&#xD;
      previous medication throughout the trial. The study also wants to investigate the safety&#xD;
      profile of Corever during treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seated Office SBP reduction (SBP each visit-SBP visit 2)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To compare the change in office SBP measurements by cuff assessments after 8 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seated Office DBP reduction (DBP each visit-DBP visit 2)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To compare the change in office DBP measurements by cuff assessments after 8 weeks of treatment&#xD;
To compare the percentage of subjects who achieve BP goal as measured by cuff assessments (140/90 mmHg) after 8 weeks of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety-Adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety-Changes in vital signs</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety-Changes in laboratory examinations</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety-Changes in electrocardiograms</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Corever middle dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Corever high dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corever</intervention_name>
    <description>Corever</description>
    <arm_group_label>Corever high dose</arm_group_label>
    <arm_group_label>Corever middle dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>CRTA04</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are 20-90 years of age&#xD;
&#xD;
          2. Patients who belong to either one of the following categories:&#xD;
&#xD;
             With essential hypertension, as measured by office BP and are not on antihypertensive&#xD;
             treatment at screening .&#xD;
&#xD;
             With uncontrolled hypertension despite treatment with up to 2 antihypertensive agents,&#xD;
             and the type and dose of the agents shall be maintained for at least 28 days prior to&#xD;
             entering this trial.&#xD;
&#xD;
          3. Agree to and are able to follow the study procedures.&#xD;
&#xD;
          4. Understand the nature of the study, and have signed informed consent forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any of the following conditions:&#xD;
&#xD;
               -  Malignant hypertension&#xD;
&#xD;
               -  Secondary hypertension&#xD;
&#xD;
               -  Average sitting SBP â‰¥ 180 mmHg&#xD;
&#xD;
               -  Advanced hypertensive retinopathy&#xD;
&#xD;
               -  Type 1 diabetes&#xD;
&#xD;
               -  Acute coronary syndrome&#xD;
&#xD;
               -  Clinical significant valvular disease&#xD;
&#xD;
               -  Hypertrophic cardiomyopathies&#xD;
&#xD;
               -  New York Heart Association class III -IV congestive HF&#xD;
&#xD;
               -  Second or third degree atrioventricular block or history of sick sinus syndrome&#xD;
                  unless a pacemaker is in place&#xD;
&#xD;
               -  Atrial fibrillation&#xD;
&#xD;
               -  Sinus bradycardia (&lt;60 bpm)&#xD;
&#xD;
               -  Asthma&#xD;
&#xD;
               -  Stroke within 3 months&#xD;
&#xD;
               -  Cancer with expected survival less than 3 years&#xD;
&#xD;
               -  A difference of &gt; 20 mmHg for SBP or &gt; 10 mmHg for DBP between arms at screening&#xD;
&#xD;
               -  Severe hepatic impairment&#xD;
&#xD;
               -  A history of a serious hypersensitivity reaction.&#xD;
&#xD;
          2. Patients with clinically significant abnormalities.&#xD;
&#xD;
          3. Patients with known contraindication to Corever.&#xD;
&#xD;
          4. Female patients who are pregnant or lactating.&#xD;
&#xD;
          5. 5. Male or female patients of child-bearing potential who do not agree to use an&#xD;
             effective method of contraception during the study.&#xD;
&#xD;
          6. Patients is currently participating in any other clinical trial within 30 days&#xD;
&#xD;
          7. Patients need to be treated with the permitted medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chern-En Chiang, M.D., Ph.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corever</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

